<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3393">
  <stage>Registered</stage>
  <submitdate>7/12/2011</submitdate>
  <approvaldate>7/12/2011</approvaldate>
  <nctid>NCT01489046</nctid>
  <trial_identification>
    <studytitle>Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive</studytitle>
    <scientifictitle>A Phase IIb Randomized, Controlled, Partially Blinded Clinical Trial to Investigate Safety, Efficacy and Dose-response of BMS-986001 in Treatment-naive HIV-1-infected Subjects, Followed by an Open-label Period on the Recommended Dose</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-003329-89</secondaryid>
    <secondaryid>AI467-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HIV-1 Infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-986001
Treatment: drugs - BMS-986001
Treatment: drugs - BMS-986001
Treatment: drugs - Placebo matching with BMS-986001
Treatment: drugs - Efavirenz
Treatment: drugs - Lamivudine
Treatment: drugs - Tenofovir

Experimental: Arm 1: BMS-986001 (100 mg) + Placebo + Efavirenz + Lamivudine - 

Experimental: Arm 2: BMS-986001 (200 mg) + Placebo + Efavirenz + Lamivudine - 

Experimental: Arm 3: BMS-986001 (400 mg) + Efavirenz + Lamivudine - 

Experimental: Arm 4: Tenofovir (300 mg) + Efavirenz + Lamivudine - 


Treatment: drugs: BMS-986001
Capsules, Oral, 100 mg, Once daily, At least 48 weeks

Treatment: drugs: BMS-986001
Capsules, Oral, 200 mg, Once daily, At least 48 weeks

Treatment: drugs: BMS-986001
Capsules, Oral, 400 mg, Once daily, At least 48 weeks

Treatment: drugs: Placebo matching with BMS-986001
Capsules, Oral, 0 mg, Once daily, At least 48 weeks

Treatment: drugs: Efavirenz
Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase

Treatment: drugs: Lamivudine
Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase

Treatment: drugs: Tenofovir
Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of subjects with plasma HIV-1 RNA &lt; 50 c/mL as measured by polymerase chain reaction (PCR) analyses</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety as measured by numbers of subjects with Serious Adverse Events (SAEs) and numbers of subjects with Adverse Events (AEs) leading to discontinuations</outcome>
      <timepoint>Week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with plasma HIV-1 RNA &lt; 50 c/mL as measured by PCR analyses</outcome>
      <timepoint>Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety as measured by numbers of subjects with SAEs and numbers of subjects with AEs leading to discontinuation</outcome>
      <timepoint>Weeks 48 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes from baseline in CD4+ T-cell counts</outcome>
      <timepoint>Weeks 24, 48, and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Numbers of subjects with virologic failure who exhibit genotypic substitutions in viral Ribonucleic acid (RNA)</outcome>
      <timepoint>Weeks 24, 48, and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed concentration (Cmax) of BMS-986001 when co-administered with EFV and 3TC</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time of maximum observed concentration (Tmax) of BMS-986001 when co-administered with EFV and 3TC</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough plasma concentration at 24 h post observed dose (Cmin) of BMS-986001 when co-administered with EFV and 3TC</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough plasma concentration pre-dose (C0) of BMS-986001 when co-administered with EFV and 3TC</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve in one dosing interval [AUC(0-24)] of BMS-986001 when co-administered with EFV and 3TC</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Average steady-state plasma concentration (Css,avg) of BMS-986001 when co-administered with EFV and 3TC</outcome>
      <timepoint>Week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  At least 18 years of age, (or minimum age as determined by local regulatory or as
             legal requirements dictate, whichever is higher)

          -  Plasma HIV-1 RNA &gt; 5000 copies/mL

          -  Antiretroviral treatment-naive; defined as no current or previous exposure to &gt; 1 week
             of an antiretroviral drug

          -  CD4+ T-cell count &gt; 200 cells/mm3</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Resistance to any of the study medications [Tenofovir Disoproxil Fumarate(TDF),
             Efavirenz (EFV), Lamivudine (3TC)] or to HIV Protease Inhibitors (PIs)

          -  Contraindications to any of the study drugs</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>297</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Local Institution - Darlinghurst</hospital>
    <hospital>Local Institution - Liverpool</hospital>
    <hospital>Local Institution - Melbourne</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>1871 - Liverpool</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Cundinamarca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Distrito Federal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Lima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Peru</country>
      <state>Loreto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Free State</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Kwa Zulu Natal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Western Cape</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Cape Town</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban KZN</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Durban</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Khon Kaen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Nontaburi</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to identify at least one dose of BMS-986001 which is safe, well
      tolerated, and efficacious when combined with Efavirenz (EFV) + Lamivudine (3TC) for
      treatment-naive Human Immunodeficiency Virus 1 (HIV-1) infected subjects</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01489046</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>